查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1552737

PCSK9 抑制剂市场（药物类型：Alirocumab、Evolocumab、Inclisiran 和 Tafolecimab；形式：全人源化单株抗体和 siRNA）- 2024-2034 年全球产业分析、规模、份额、成长、趋势和预测

PCSK9 Inhibitor Market (Drug Type: Alirocumab, Evolocumab, Inclisiran, and Tafolecimab; and Modality: Fully-humanized Monoclonal Antibodies and siRNA) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 134 Pages | 商品交期: 2-10个工作天内

价格

PCSK9 抑制剂市场 - 报告范围

TMR 关于全球 PCSK9 抑制剂市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。年期间，考虑2024年为基准年，2034年为预测年。报告中也提供了2024年至2034年全球PCSK9抑制剂市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解 PCSK9 抑制剂市场。

市场概况
2023年市场价值 17 亿美元
2034 年市场价值 93 亿美元
复合年增长率 16.9%

该报告深入探讨了全球 PCSK9 抑制剂市场的竞争格局。全球 PCSK9 抑制剂市场的主要参与者已经确定，并且对每位参与者的各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球 PCSK9 抑制剂市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：按药物类型

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依药物类型，2020-2034
    • 阿利罗库单抗
    • 依洛单抗
    • 因克利西兰
    • 他福莱西单抗
  • 市场吸引力：按药物类型

第 7 章：全球市场分析与预测：按模式

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按模式，2020-2034
    • 全人源化单株抗体
    • siRNA
  • 市场吸引力：依形态分类

第 8 章：全球市场分析与预测：依指标分类

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依指标划分，2020-2034
    • 原发性高血脂症
    • 家族性高胆固醇血症
    • 其他心血管疾病
  • 市场吸引力：依指标分类

第 9 章：全球市场分析与预测：按配销通路

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2020-2034
    • 医院药房
    • 零售药局
    • 网路药局
  • 市场吸引力：按配销通路划分

第 10 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按地区

第 11 章：北美市场分析与预测

第 12 章：欧洲市场分析与预测

第 13 章：亚太市场分析与预测

第 14 章：拉丁美洲市场分析与预测

第 15 章：中东和非洲市场分析与预测

第16章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • Novartis AG
    • Regeneron Pharmaceuticals
    • Amgen Inc.
    • Innovent Bio
    • LIB Therapeutics
    • Shanghai Junshi Biosciences Co., Ltd.
    • Merck & Co., Inc.
    • AstraZeneca plc
Product Code: TMRGL83528

PCSK9 Inhibitor Market - Scope of Report

TMR's report on the global PCSK9 inhibitor market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global PCSK9 inhibitor market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global PCSK9 inhibitor market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the PCSK9 inhibitor market.

Market Snapshot
Market Value in 2023US$ 1.7 Bn
Market Value in 2034US$ 9.3 Bn
CAGR16.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global PCSK9 inhibitor market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global PCSK9 inhibitor market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global PCSK9 inhibitor market.

The report delves into the competitive landscape of the global PCSK9 inhibitor market. Key players operating in the global PCSK9 inhibitor market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global PCSK9 inhibitor market profiled in this report.

Key Questions Answered in Global PCSK9 inhibitor Market Report:

  • What is the sales/revenue generated by PCSK9 inhibitor across all regions during the forecast period?
  • What are the opportunities in the global PCSK9 inhibitor market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

PCSK9 Inhibitor Market - Research Objectives and Research Approach

The comprehensive report on the global PCSK9 inhibitor market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global PCSK9 inhibitor market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global PCSK9 inhibitor market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global PCSK9 Inhibitors Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global PCSK9 Inhibitors Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global PCSK9 Inhibitors Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2020-2034
    • 6.3.1. Alirocumab
    • 6.3.2. Evolocumab
    • 6.3.3. Inclisiran
    • 6.3.4. Tafolecimab
  • 6.4. Market Attractiveness, by Drug Type

7. Global PCSK9 Inhibitors Market Analysis and Forecast, by Modality

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Modality, 2020-2034
    • 7.3.1. Fully-humanized Monoclonal Antibodies
    • 7.3.2. siRNA
  • 7.4. Market Attractiveness, by Modality

8. Global PCSK9 Inhibitors Market Analysis and Forecast, by Indication

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Indication, 2020-2034
    • 8.3.1. Primary Hyperlipidemia
    • 8.3.2. Familial Hyper Cholesterolemia
    • 8.3.3. Other Cardiovascular Disorders
  • 8.4. Market Attractiveness, by Indication

9. Global PCSK9 Inhibitors Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global PCSK9 Inhibitors Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America PCSK9 Inhibitors Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Type, 2020-2034
    • 11.2.1. Alirocumab
    • 11.2.2. Evolocumab
    • 11.2.3. Inclisiran
    • 11.2.4. Tafolecimab
  • 11.3. Market Attractiveness, by Drug Type
  • 11.4. Market Value Forecast, by Modality, 2020-2034
    • 11.4.1. Fully-humanized Monoclonal Antibodies
    • 11.4.2. siRNA
  • 11.5. Market Attractiveness, by Modality
  • 11.6. Market Value Forecast, by Indication, 2020-2034
    • 11.6.1. Primary Hyperlipidemia
    • 11.6.2. Familial Hyper Cholesterolemia
    • 11.6.3. Other Cardiovascular Disorders
  • 11.7. Market Attractiveness, by Indication
  • 11.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.8.1. Hospital Pharmacies
    • 11.8.2. Retail Pharmacies
    • 11.8.3. Online Pharmacies
  • 11.9. Market Attractiveness, by Distribution Channel
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Drug Type
    • 11.11.2. By Modality
    • 11.11.3. By Indication
    • 11.11.4. By Distribution Channel
    • 11.11.5. By Country

12. Europe PCSK9 Inhibitors Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Type, 2020-2034
    • 12.2.1. Alirocumab
    • 12.2.2. Evolocumab
    • 12.2.3. Inclisiran
    • 12.2.4. Tafolecimab
  • 12.3. Market Attractiveness, by Drug Type
  • 12.4. Market Value Forecast, by Modality, 2020-2034
    • 12.4.1. Fully-humanized Monoclonal Antibodies
    • 12.4.2. siRNA
  • 12.5. Market Attractiveness, by Modality
  • 12.6. Market Value Forecast, by Indication, 2020-2034
    • 12.6.1. Primary Hyperlipidemia
    • 12.6.2. Familial Hyper Cholesterolemia
    • 12.6.3. Other Cardiovascular Disorders
  • 12.7. Market Attractiveness, by Indication
  • 12.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.8.1. Hospital Pharmacies
    • 12.8.2. Retail Pharmacies
    • 12.8.3. Online Pharmacies
  • 12.9. Market Attractiveness, by Distribution Channel
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Drug Type
    • 12.11.2. By Modality
    • 12.11.3. By Indication
    • 12.11.4. By Distribution Channel
    • 12.11.5. By Country/Sub-region

13. Asia Pacific PCSK9 Inhibitors Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Type, 2020-2034
    • 13.2.1. Alirocumab
    • 13.2.2. Evolocumab
    • 13.2.3. Inclisiran
    • 13.2.4. Tafolecimab
  • 13.3. Market Attractiveness, by Drug Type
  • 13.4. Market Value Forecast, by Modality, 2020-2034
    • 13.4.1. Fully-humanized Monoclonal Antibodies
    • 13.4.2. siRNA
  • 13.5. Market Attractiveness, by Modality
  • 13.6. Market Value Forecast, by Indication, 2020-2034
    • 13.6.1. Primary Hyperlipidemia
    • 13.6.2. Familial Hyper Cholesterolemia
    • 13.6.3. Other Cardiovascular Disorders
  • 13.7. Market Attractiveness, by Indication
  • 13.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.8.1. Hospital Pharmacies
    • 13.8.2. Retail Pharmacies
    • 13.8.3. Online Pharmacies
  • 13.9. Market Attractiveness, by Distribution Channel
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Drug Type
    • 13.11.2. By Modality
    • 13.11.3. By Indication
    • 13.11.4. By Distribution Channel
    • 13.11.5. By Country/Sub-region

14. Latin America PCSK9 Inhibitors Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Type, 2020-2034
    • 14.2.1. Alirocumab
    • 14.2.2. Evolocumab
    • 14.2.3. Inclisiran
    • 14.2.4. Tafolecimab
  • 14.3. Market Attractiveness, by Drug Type
  • 14.4. Market Value Forecast, by Modality, 2020-2034
    • 14.4.1. Fully-humanized Monoclonal Antibodies
    • 14.4.2. siRNA
  • 14.5. Market Attractiveness, by Modality
  • 14.6. Market Value Forecast, by Indication, 2020-2034
    • 14.6.1. Primary Hyperlipidemia
    • 14.6.2. Familial Hyper Cholesterolemia
    • 14.6.3. Other Cardiovascular Disorders
  • 14.7. Market Attractiveness, by Indication
  • 14.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.8.1. Hospital Pharmacies
    • 14.8.2. Retail Pharmacies
    • 14.8.3. Online Pharmacies
  • 14.9. Market Attractiveness, by Distribution Channel
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Drug Type
    • 14.11.2. By Modality
    • 14.11.3. By Indication
    • 14.11.4. By Distribution Channel
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa PCSK9 Inhibitors Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Type, 2020-2034
    • 15.2.1. Alirocumab
    • 15.2.2. Evolocumab
    • 15.2.3. Inclisiran
    • 15.2.4. Tafolecimab
  • 15.3. Market Attractiveness, by Drug Type
  • 15.4. Market Value Forecast, by Modality, 2020-2034
    • 15.4.1. Fully-humanized Monoclonal Antibodies
    • 15.4.2. siRNA
  • 15.5. Market Attractiveness, by Modality
  • 15.6. Market Value Forecast, by Indication, 2020-2034
    • 15.6.1. Primary Hyperlipidemia
    • 15.6.2. Familial Hyper Cholesterolemia
    • 15.6.3. Other Cardiovascular Disorders
  • 15.7. Market Attractiveness, by Indication
  • 15.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 15.8.1. Hospital Pharmacies
    • 15.8.2. Retail Pharmacies
    • 15.8.3. Online Pharmacies
  • 15.9. Market Attractiveness, by Distribution Channel
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Drug Type
    • 15.11.2. By Modality
    • 15.11.3. By Indication
    • 15.11.4. By Distribution Channel
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Novartis AG
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Regeneron Pharmaceuticals
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Amgen Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Innovent Bio
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. LIB Therapeutics
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Shanghai Junshi Biosciences Co., Ltd.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Merck & Co., Inc.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. AstraZeneca plc
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview

List of Tables

  • Table 01: Global PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 02: Global PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 03: Global PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 05: Global PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 06: North America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 07: North America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 08: North America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 9: North America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 10: North America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 11: Europe PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 13: Europe PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 14: Europe PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 15: Europe PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 16: Asia Pacific PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 18: Asia Pacific PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 19: Asia Pacific PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 20: Asia Pacific PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Latin America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 23: Latin America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 24: Latin America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 25: Latin America PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 26: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Drug Type, 2020-2034
  • Table 28: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Modality, 2020-2034
  • Table 29: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Indication, 2020-2034
  • Table 30: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global PCSK9 Inhibitors Market Size (US$ Bn), by Region, 2023 and 2034
  • Figure 02: Global PCSK9 Inhibitors Market Revenue (US$ Bn), by Drug Type, 2023
  • Figure 03: Global PCSK9 Inhibitors Market Value Share, by Drug Type, 2023
  • Figure 04: Global PCSK9 Inhibitors Market Revenue (US$ Bn), by Modality, 2023
  • Figure 05: Global PCSK9 Inhibitors Market Value Share, by Modality, 2023
  • Figure 06: Global PCSK9 Inhibitors Market Revenue (US$ Bn), by Indication, 2023
  • Figure 07: Global PCSK9 Inhibitors Market Value Share, by Indication, 2023
  • Figure 08: Global PCSK9 Inhibitors Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 09: Global PCSK9 Inhibitors Market Value Share, by Distribution Channel, 2023
  • Figure 10: Global PCSK9 Inhibitors Market Value Share, by Region, 2023
  • Figure 11: Global PCSK9 Inhibitors Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 12: Global PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 13: Global PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 14: Global PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 15: Global PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 16: Global PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 17: Global PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 18: Global PCSK9 Inhibitors Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 19: Global PCSK9 Inhibitors Market Value Share, by Distribution Channel, 2023
  • Figure 20: Global PCSK9 Inhibitors Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global PCSK9 Inhibitors Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America PCSK9 Inhibitors Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America PCSK9 Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America PCSK9 Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 26: North America PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 27: North America PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 28: North America PCSK9 Inhibitors Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 29: North America PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 30: North America PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 31: North America PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 32: North America PCSK9 Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 33: Europe PCSK9 Inhibitors Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe PCSK9 Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe PCSK9 Inhibitors Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 37: Europe PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 38: Europe PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 39: Europe PCSK9 Inhibitors Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 40: Europe PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 41: Europe PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 42: Europe PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 43: Europe PCSK9 Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 44: Asia Pacific PCSK9 Inhibitors Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific PCSK9 Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific PCSK9 Inhibitors Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 48: Asia Pacific PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 49: Asia Pacific PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 50: Asia Pacific PCSK9 Inhibitors Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Asia Pacific PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 52: Asia Pacific PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 53: Asia Pacific PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 54: Asia Pacific PCSK9 Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2023-2034
  • Figure 55: Latin America PCSK9 Inhibitors Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America PCSK9 Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America PCSK9 Inhibitors Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 59: Latin America PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 60: Latin America PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 61: Latin America PCSK9 Inhibitors Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 62: Latin America PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 63: Latin America PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 64: Latin America PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 65: Latin America PCSK9 Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 66: Middle East & Africa PCSK9 Inhibitors Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa PCSK9 Inhibitors Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa PCSK9 Inhibitors Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa PCSK9 Inhibitors Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 70: Middle East & Africa PCSK9 Inhibitors Market Value Share Analysis, by Modality, 2023 and 2034
  • Figure 71: Middle East & Africa PCSK9 Inhibitors Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 72: Middle East & Africa PCSK9 Inhibitors Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 73: Middle East & Africa PCSK9 Inhibitors Market Attractiveness Analysis, by Drug Type, 2024-2034
  • Figure 74: Middle East & Africa PCSK9 Inhibitors Market Attractiveness Analysis, by Modality, 2024-2034
  • Figure 75: Middle East & Africa PCSK9 Inhibitors Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 76: Middle East & Africa PCSK9 Inhibitors Market Attractiveness Analysis, by Distribution Channel, 2024-2034